% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • jrabelow1 jrabelow1 Oct 30, 2013 9:43 PM Flag

    $93 pricre target from $88

    Vertex Pharmaceuticals (NASDAQ:VRTX): Baird believes that the weakness in Vertex following third-quarter earnings is a buying opportunity, pointing to Vertex’s decision to eliminate a substantial portion of the Hep-C infrastructure. The cost-saving measure will yield a favorable impact to shareholders, and Baird is therefore raising its price target to $93 from $88. Vertex shares remain Outperform rated.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
80.76-2.16(-2.60%)Oct 21 4:00 PMEDT